Pfizer takes the lead of the COVID race
Pfizer Inc takes the lead as it announces a 95% success on the final outcome from the late-stage trial of its vaccine for COVID-19. The company stated it had already prepared the 2-month safety data and now its only a matter of time for authorization.
The information from the 2 vaccines have surpassed expectations as mRNA (messenger RNA), raised the hopes to ending this pandemic that has killed more than 1.3 million so far.
Pfizer stated that it hopes to make as much as 50 million vaccines in 2020, a number that can cover around 25 million individuals, and afterwards to push to produce up to 1.3 billion doses for 2021.
Moderna Inc on Monday delivered data close to those of Pfizer, having a 94.5% of effectiveness.
Of the other many drugmakers and researchers in the same race as Moderna and Pfizer, we are expecting to see data by AstraZeneca Plc with the University of Oxford in November or December, with Johnsons & Johnsons also on the same path for deliveries in 2020.